Patents by Inventor Zih-Fei Cheng

Zih-Fei Cheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230036481
    Abstract: The present invention provides a human CD16+ natural killer cell line and a CAR-expressing human CD16+ natural killer cell line. These human CD16+ natural killer cell line and a CAR-expressing human CD16+ natural killer cell line does not include synthetic, genetically modified or purposely deliberately delivered polynucleotide encoding the CD16 receptor and are non-tumorigenic cell lines. Therefore, this human CD16+ natural killer cell line and a CAR-expressing human CD16+ natural killer cell line might provide considerable long-term safety for disease treatment.
    Type: Application
    Filed: January 15, 2021
    Publication date: February 2, 2023
    Applicant: Acepodia Biotechnologies Ltd.
    Inventors: SAI-WEN TANG, ZIH-FEI CHENG, CHIA-YUN LEE, HAO-KANG LI, HSIU-PING YANG, CHING-WEN HSIAO, SEN HEN YANG, TAI-SHENG WU, YAN-LIANG LIN, YAN-DA LAI, SHIH-CHIA HSIAO
  • Publication number: 20220073878
    Abstract: The present invention provides a human CD16+ natural killer cell line. This human CD16+ natural killer cell line does not include synthetic, genetically modified or deliberately delivered polynucleotide encoding the CD16 receptor and is a non-tumorigenic cell line. Therefore, this human CD16+ natural killer cell line might provide considerable long-term safety for disease treatment.
    Type: Application
    Filed: January 16, 2020
    Publication date: March 10, 2022
    Applicant: Acepodia Biotechnologies Ltd.
    Inventors: Zih-Fei Cheng, Chia-Yun Lee, Hao-Kang Li, Yan-Liang Lin, Ching-Wen Hsiao, Yan-Da Lai, Yu-Pei Cheng, Hsiu-Ping Yang, Shih-Chia Hsiao